Monday, June 6, 2011

中國藥材GAP戰略思維!!

十二五 末中藥產業規模預計達萬億 上海證券報 2011-06-03在干旱、游資炒作等綜合因素的影響下,今年來,中藥材價格出現新一輪漲價潮。然而這一切并不能阻擋我國中藥產業的迅猛發展。在干旱、游資炒作等綜合因素的影響下,今年來,中藥材價格出現新一輪漲價潮。然而這一切并不能阻擋我國中藥產業的迅猛發展。 近日,中國中藥協會會長房書亭表示,預計到2015年,中藥產業產值將突破一萬億元,而產業信息化將在很大程度上糾正盲目生產、資源浪費和價格不合理的現象。

中藥產業快速發展 近幾年,我國的中藥產業取得了長足的發展,中藥產業產值年平均增長20%以上,高於醫藥行業的平均水平,形成近千億元的產業規模。中藥材年用量25年來從40萬噸增加到了120萬噸以上。 據中藥協會相關人士介紹,"十一五"期間,我國加快了GMP改造和建設步伐,淘汰了一批產能落后的企業,使中藥生產企業整體能力得到了增強,中成藥總產值從2005年的1202.3億元上升到2009年的2054.4億元。 2010年,我國中藥制造業資產突破3000億元,同比增長18%左右,增速比上年同期上升近5個百分點;企業數量達2300多個;累計完成固定資產投資總額近500億元,同比增長16%左右。 在中投顧問醫藥行業研究員郭凡禮看來,中醫藥產業的前景十分光明,在新醫改共計8500億的巨額投資里,有一部分就是用於支持我國中藥產業的發展。如今國家把國民健康的重點放在病前的控制而非病后的治療,而中藥"治未病"的概念已深入人心,隨著人們對養生保健的重視,我國中藥產業將獲得進一步的發展。 近日,我國生物技術發展中心發布報告指出,未來十余年,中國將加速實現中醫藥現代化,進一步完善中醫藥理論體系,大幅提高中醫診斷與治療水平,使更多人、更多國家接受和享用中醫技術。同時,中國還將逐步實現中藥現代化,逐步完善并廣泛應用中藥標準體系,系統化、標準化、規模化中藥材的種植、生產和加工,提高中藥創新能力。 在此背景下,國內各大中藥企業的積極性也水漲船高。據梧州中恒集團副總經理陳明表示,在未來的發展中,中恒將通過并購參股、合作等多種方式,優化生產要素,構筑集約化、規模化、技術領先、品牌突出、綜合競爭力強的中恒制藥企業。提高廣西藥業的整體實力和競爭力。

政府將"監管+扶持"兩手抓 目前,中藥材價格的高企成為我國中醫藥產業快速發展的一個最大障礙。中藥材天地網的價格指數統計顯示,截至5月29日,以中國成都中藥材價格指數的基期算起,今年以來的指數上漲約16.2%,而監測期內最低值與最高值間相差幅度達到38.7%,上周中藥材價格指數上漲4.44%,再創2009年以來新高。在中藥材天地網副總經理賈海彬看來,多重因素推動了中藥材價格的新一輪上漲,首先,自2000 年以來國內中藥材種植面積大幅減少,全國大部分地區自然災害頻繁,尤其今年以來旱災情況嚴峻,使得中藥材產量逐年減少。供應減少是中藥材價格上漲的重要因素。其次,中藥材種植和收割的人工成本以及運輸成本均逐年提高,直接導致了中藥材貿易成本上升。此外,人們對中藥需求的增長以及部分游資炒作也助推了中藥材價格上漲。藥材漲價,已經直接沖擊到下游企業的利潤,一些中小企業曾一度停產。為了控制成本,康美、廣藥、修正藥業等不少企業從2010年開始已經加快了自建基地的步伐。自2010年以來,廣藥集團白云山和黃中藥已先后在云南文山和黑龍江大慶兩地,分別建立了一萬畝三七GAP基地和5萬畝板藍根GAP基地。加上重慶的大巴山潘高壽川貝母GAP種植基地等,廣藥集團的藥材基地達20個,是全國擁有中藥材基地最多的藥企之一。對於此輪中藥材漲價潮,到底哪些個股會從中受益呢?分析人士表示,處於中藥上游的飲片類企業或將成為少數受益最大的企業。另外,擁有藥材基地的上市公司也將從中受益。事實上,為了使中藥材回歸健康發展道路,政府將進行"監管+扶持"兩手抓。中國中藥協會會長房書亭就向記者表示,大宗藥材的國家戰略儲備工作正在研究落實中。另外,就在上個月,工信部公布《2011年度中藥材生產扶持項目申報指南》(下稱《指南》) 。"2011年扶持的重點主要在基地建設上,從常用大宗藥材入手,解決藥材缺口。"工信部項目組相關負責人張軍表示。張軍表示,"十二五"期間,大約要扶持100個藥材品種,其中70%是常用大宗藥材,30%是野生瀕危藥材,以解決大宗藥材的需求缺口。按照分步實施的原則,2011年將重點支持35個品種,其中包括甘草、三七、太子參等26種常用大宗藥材和重樓、川貝母、沉香、豬苓、紅景天、雷公藤、麝香、蟾酥、烏梢蛇9種瀕危稀缺藥材。

中國藥價調整:中藥產業如何因應?!

不堪原材料成本控制壓力 藥企快速延伸產業鏈避險  北京新浪網 (2011-06-07) 2008年,康美藥業購入上千噸"三七",中藥漲價受益最大 藥材價格猛漲拉低毛利率,而中成藥價格卻一再"被"降價。最近的兩次降價分別是3月28日發改委正式實施了第27輪藥品降價令、4月15日山東省下通知調整藥價。其中,山東省的調價以中成藥為主,化學藥品只占了22%。雖然近日有消息稱102種醫保目錄中成藥有望提價,但此消息未獲得發改委正面回應。在夾縫中生存的藥企不約而同地踏上前景廣闊的"大健康"道路。華泰聯合證券就很看好中成藥行業的投資價值,認為中成藥企業在藥妝、保健品等大健康領域大有作為。研究報告顯示,社會發展、收入增加、觀念改變帶來醫藥消費市場的升級與分化,藥品消費市場由過去單純治療向高端的預防、保健、康複等方向分化發展。在政策對藥品價格持續管控的背景下,通過模式創新、產品創新延伸醫藥產業鏈是醫藥企業持續發展的現實選擇。

瞄准中藥消費品  與化學藥相比,中成藥的群眾基礎更好,一旦調價也將產生更深遠的影響。2009年《國家基本藥物目錄》囊括了臨床常用的大部分中成藥,共計102種。依據《基本藥物制度》,基本藥物最高零售價由國家發改委制定,省級政府通過集中採購定出地方中標價。中藥材在持續多年低價徘徊後終於因2010年的天災引發井噴漲勢。中藥材天地網數據顯示,在2010年5月至2011年5月期間,藥市整體依舊呈現上升勢頭。而藥企在《基本藥物制度》的枷鎖下,無法決定基本藥物價格,而藥妝、保健品的價格就相對靈活多了。以中藥為主營項目的藥企,把觸角從核心產品延伸至主打調理功能的牙膏、洗髮水等中藥消費品上,雲南白藥便是其中的佼佼者。2010年雲南白藥營收跨上百億元的新階梯,公司提出的企業戰略為"新白藥、大健康",著力耕耘藥品與健康產品兩大領域。雲南白藥集團股份有限公司副總經理王錦近日向媒體透露,在去年100個億的銷售額中,雲南白藥牙膏已達到12個億。事實上,雲南白藥多年前就開始打造白藥衍生產品。除明星產品白藥牙膏,還有養元清中藥去屑洗護髮產品和千草堂止癢理膚洗護等。

開發中藥養生領域 廣藥集團的"護身法寶"則是王老吉涼茶,儘管廣藥與加多寶因王老吉品牌歸屬權吵得不可開交,但不可否認,王老吉涼茶已經成為了我國涼茶第一品牌。興業證券研究報告顯示,加多寶紅罐裝王老吉涼茶年銷售收入超過 150 億,廣州藥業旗下王老吉藥業生產的綠盒裝王老吉涼茶年銷售收入已超過 10 億。在廣藥集團公布的"十二五"規劃中,大健康產業被定位為"六大發展板塊"之一。目前,廣藥集團的大健康產業已初具規模,在全國範圍內的20個GAP藥材基地可很好地保障廣藥集團在中藥養生領域大展拳腳。不僅有王老吉涼茶和白雲山涼茶,廣藥集團目前處於開發階段的大多為中藥衍生健康消費產品,包括白雲山的神龍養生酒、陳李濟和敬修堂的藥用化妝品、王老吉的潤喉糖、潘高壽的龜苓膏等。興業證券認為,"廣州藥業"以集團整合王老吉品牌資源為依托,通過旗下王老吉藥業為平台發展該產業的成績值得期待。而廣州藥業前總經理施少斌曾表示,公司大健康產業要爭取在"十二五"末實現500億元銷售目標。

"大健康"是長久之策 說到"大健康"概念,不能不提到中藥巨頭修正藥業,公司在大健康方面可謂不遺余力。目前,修正藥業人參種植量已占長白山整個人參種植量的40%~45%,人參產業項目旗下的修正牌人參系列的醫藥、食品、保健品、化妝品等已相繼問市。而唯一一家從中藥漲價中受益匪淺的上市公司是康美藥業,早在2008年公司便在雲南文山市場購入上千噸三七,2009年末開始的西南大旱使三七減產,價格隨之飆升。康美藥業2010年實現營業收入33.08億元,同比增長39.19%;歸屬於上市公司股東的淨利潤7.15億元,同比增長42.67%。如果說藥價上漲可能是曇花一現,那大健康產業則是公司穩定盈利的保障。康美藥業預計投入1000萬元在廣州成立藥物研究院,開展中成藥、藥妝、紅參精細化研究等工作,未來可能將在北京、上海、成都等地建立分院,人數規模100多人,從研究和信息兩方面著手,有效提升長期競爭力。

台灣抗生素新藥老藥同步吸睛

浩鼎生技 新藥明年上市 【2011/06/07 經濟日報】由富邦、潤泰、永豐餘等集團轉投資的美商Optimer製藥公司,旗下抗生素新藥DIFCID 正式通過美國食品藥物管理局(FDA)核准上市,可創造營收5億美元(約新台幣 143億元),新藥將透過子公司台灣浩鼎生技明年在台上市,市場超過10億元。成立於1998年的Optimer,由中研院院長翁啟惠與旅美華人張念慈共同創辦,公司創立初期股東多數來自台灣,台灣浩鼎執行長許友恭表示,已核准上市的DIFICID是一種新型抗生素,專門治療偽膜性大腸炎,這項藥物歐洲市場在今年初授權給日商阿斯特拉藥廠。許友恭表示,這項新型抗生素5月27日通過FDA許可上市後,將與另一美商藥廠簽訂兩年合作合約,要讓此新產品三到五年內在美國市場創造年5億美元業績。許友恭指出,DIFICID是截至目前為止,全世界第一項專門對付偽膜性腸炎的抗生素,由於藥效明確、藥性溫和,而成為美國FDA今年第一個核准的抗生素新藥。業界指出,台灣生技業在抗生素藥物研究有成的公司除了Optimer之外,還有永豐餘轉投資太景生技的抗生素新藥「奈諾沙星,目前已進入臨床三期,大陸市場明年也可望上市, 此外,東洋生產的學名藥克痢黴素,也是目前製藥業常用的抗生素之一。法人指出,預估Optimer在美國推出後將寡佔市場。據估計,美國每年感染偽膜性腸炎的人約達90萬人,DIFICID推出後可望占有超過三分之一的市場,而除了美國市場,Optimer也在規劃亞洲市場的藥品上市機會。分析師指出,台灣浩鼎在今年第三季申請藥證後,明年可望上市,保守預估台灣潛在市場每年約1.5萬個病患。若以美元價位來推算,台灣市場規模也在10億元左右。浩鼎表示,若明年DIFCID在台申請藥證順利,公司也將申請上興櫃後掛牌上市。

年度食品管理預算遠低於 建國百年慶祝活動?

TFDA預算低 林杰樑:食品安全未獲重視  2011/6/5 自由時報  桃園縣政府衛生局 4日針對縣內曾使用過金果王公司產品的飯店、餐廳,稽查是否仍存有含塑化劑成分的果汁。塑化劑風暴讓台灣各界再度重視食品衛生安全。在三聚氰胺毒奶事件後,衛生署成立「食品藥物管理局」(TFDA)為全民的食品藥物安全把關,但今年TFDA編列食品管理業務預算僅有新台幣1.2億元,還較去年少了3千萬,平均每個國人只分到5.21元。歷經塑化劑風暴,林口長庚醫院臨床毒物科主任林杰樑指出,TFDA的升級只是換湯不換藥,人力不足、預算也不夠,「根本就是一個騙局」。民進黨立委黃淑英表示,翻開預算書,文建會今年補助各地政府辦理建國100年慶祝活動就編了5.7億元,相較之下TFDA食品管理業務預算,實在是少得可憐。TFDA一年的預算只有22億到23億左右,分給2,300萬人,1人分不到100元,且這100元之中,食品只佔一部分,還要包括藥妝及檢驗;直接與食品管理相關預算更只有約1.2億元,平均下來每人更只有5.21元。林杰樑表示,台灣業者如此不可信,這樣的經費真的太少了。依據監院調查報告,2008年美國每位國民分配到的食品衛生管理費用為160元、英國158元、香港458元。台灣每人不到100元的預算,已差其他國家一大截,更何況是每人5.21元的食品管理預算。台灣的食品衛生安全管理除預算不足,還有後天的人力失調。立委黃淑英表示,衛生署一再表示,TFDA成立之後,共增加了113名人力,但仔細分析發現食品組的人力從改制前的29人,到改制後只增加14人。這14人中,多為處理目前標檢局執行的業務,實際處理食品衛生業務的人力,估計最多增加5人,這5人所處理的業務又以餐飲衛生為主,與食品安全業務無關。林杰樑形容TFDA的成立,「根本就是一個騙局」,本以為食品安全會更受到重視,結果主管機關只能每年選幾個產品來抽驗,不然經費不夠,如果做一次食品戴奧辛抽驗,當年可能其他產品都驗不了。衛生署長邱文達則表示,接下來衛生福利部要成立,TFDA也會升級成為食品藥物衛生署,他會盡力去協調、爭取人力及預算。新聞局長楊永明表示,在多次跨部會會議中,都曾討論食品安全如何簡化管理、強化監督,像目前關注的源頭管理及食品安全的重建,也都是未來規劃重點。衛署也計畫舉辦食品安全大會,邀集專家、討論未來的修正方向。

Taiwan food scare 'dates back decades'

Asia Times 2011/06/07 TAIPEI - A range of Taiwanese-made food products have been banned in mainland China and South Korea, and recalled in the Philippines, after the discovery that one of Taiwan's leading chemicals company used a food additive on a dangerous scale over two decades, threatening the health of innumerable children. Products involved are also shipped to the United States. The scandal, involving the use of industrial plasticizer bis(2-ethylhexyl)phthalate (DEHP) in beverages, jams, syrups, jellies, calcium supplements, multivitamin tablets and other products, recalls the 2008 Chinese melamine scandal in terms of corporate greed and the risk posed to children's health. Plasticizers such as DEHP are additives that increase a material's plasticity and are used in production of all sorts of useful things, such as leather goods, rainwear, flooring, wiring and cable, food packaging materials and children's toys. Last month, Taiwanese inspectors discovered that Yu Shen Chemical Co, the island's largest emulsifier supplier added DEHP to its clouding agent on a large scale. Clouding agents, formulated with palm oil or gum arabic, are used to make processed foods look more appealing. When formulated with plasticizers such as DEHP, instead of with expensive palm oil, what's eaten and drunk looks even more tempting, and the chemical furthermore comes with the handy feature that it significantly extends shelf life. The downside to the scam, however, could hardly be any steeper: carcinogen in each contaminated unit inspected by the Taiwanese authorities topped 600 parts per million, exceeding by far the allowable daily intake of the chemical. And, closely resembling the 2008 scandal in which mainland Chinese company Sanlu added melamine, banned for use in foodstuffs, to baby powder to indicate higher levels of protein, the main victims in the Taiwan case are young children. Children who consume beverages contaminated with DEHP on a long-term basis are eight times more at risk of developing problems with their reproductive system. The males are more likely to suffer from feminization and shrinking of the penis and testicles when they become adults, girls are facing the prospect of premature development of their sexual organs. Thyroid dysfunction and fertility problems threaten these children later in life. Another shocking aspect of the worldwide unprecedented DEHP scam is its duration: insiders told investigators that similar practices have been going on for as long as two decades. Unsurprisingly, the revelations have led to panic among Taiwan's public and government. After an army of inspectors descended on the island's businesses that produce or sell food stuffs, including clinics and pharmacies, the scale of the scandal has become ever more shocking. Prosecutors allege that Yu Shen purchased as much as five tonnes of DEHP every month to make flavor and food coloring agents, selling the products to chemical and food processing factories, as well as to bakeries and pastry shops. A total of 130 food products were confirmed by the Food and Drug Administration to contain DEHP, while 95 manufacturers were found to have used the banned ingredient. A total of 244 ingredient-manufacturing companies, including several renowned brands, were found to have sourced clouding agents from Yu Sheng and Pin Han Perfumery Co, another emulsifier supplier alleged to have carried out a similar scam. A total of 40,000 kilograms of juice and jam, 980,000 bottles of tea drinks and more than 2,000 boxes of powdered probiotic products have been recalled.  127.5 barrels of emulsifiers have been confiscated.  In Taipei, the sale of 3,448 products for which businesses could not produce certificates was suspended by inspectors.  The island's four major convenience store operators - President Chain Store Corp, FamilyMart, OK-Mart and Hi-Life - have pulled all sports drinks from their shelves. The problem is not limited to Taiwan. The island's DEHP-tainted stuff had been shipped to the United States, mainland China, Hong Kong, the Philippines and Vietnam. After the Department of Health informed health authorities in these countries, Presidential Office spokesman Fang Chiang Tai-chi stated: "The incident has not only caused great public concern, but will also affect the economy and have a negative impact on Taiwan's international reputation." In terms of direct outfall, his statement at first glance appears to be no exaggeration. Companies are claiming their business has shrunk by 20% due to the scandal. Investors are turning away from food stocks and popular night markets, important for the tourism sector, have also seen sales decline significantly. Taiwanese beverages, jams, syrups, jellies and other products suspected of DEHP contamination have been banned by South Korea and mainland China, and Manila has ordered an extensive recall of Taiwanese-made food and drink products. Even so, while desperate Taiwanese parents line up at laboratories, carrying with them the products their children have been sipping for years, Taiwan's food and beverage industry accounts for a mere 4% of the island's domestic manufacturing output, which in turn contributes to about 25% of gross domestic product. In terms of exports, prepared food brought in only US$1.07 billion in 2010, and cosmetics and supplements are not even listed among Taiwan's 16 major export goods. "The most damage will be done to the catering industry, manufacturers of food and beverages, convenience stores and, for a smaller part, also the pharmaceutical and cosmetics industry," Hu Sheng-Cheng, an academic at Academia Sinica's Institute of Economics, told Asia Times Online. Hu likened the DEHP scandal to a small-to-medium-sized typhoon in terms of economic impact. "Those sectors' combined annual turnover accounts for NT$900 billion (US$30 billion), and only 10% of them is affected by the DEHP issue. If the scare lasts no longer than a month, the loss will be NT$8 billion to NT$10 billion." Next to children's health, it is the public's trust in the government and in the "Made in Taiwan" brand that will be most negatively affected, he said. And while some companies are being hit by the scandal, others can profit, according Huang Li-hsuan, professor at Taiwan's National Central University's Department of Economics. "Because most of the products involved in the DEHP scandal are essentials and part of the Taiwanese public's daily lives, consumers' flexibility isn't high," Huang said. "So if we say DEHP decreases sales of this and that product, such as soft drinks, the public will use other related products like fresh juice, mineral water, and so on, as a substitute. In other words, in the short term, DEHP will make some businesses do worse but others better." The danger of the DEHP scandal denting Taiwan's international reputation, as suggested by the Presidential Office spokesman, is also slim, according to Gary Rawnsley, a professor of Asian International Communications at the University of Leeds. Rawnsley, an expert on public diplomacy and soft power, dismissed the notion that Taiwan's image abroad could suffer anywhere as much as China's in 2008 due to the melamine scandal. "China's scandals have certainly been more prominent because they are Chinese and China garners far more media attention across the world than Taiwan", he said. The DEHP scandal "will have an effect on the manufacturers but not on Taiwan's image among the public around the world. The reason for that is it is not news here [in the UK] or elsewhere as far as I can see."

alveice Team. Powered by Blogger.